Intervention group:Panobinostat and tazemetostat are combined with immune checkpoint inhibitors pembrolizumab and ipilimumab

3 trials

Sponsors

Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Shunyi Women's & Children's Hospital of Beijing Children's Hospital

Conditions

Diffuse midline gliomaPediatric-type Diffuse High-grade Gliomas

Early Phase 1

Evaluation of the Clinical Efficacy of Epigenetic Agents Combined with Immune Checkpoint Inhibitors in the Treatment of Pediatric-type Diffuse High-grade Gliomas

RecruitingChiCTR2500107892

Beijing Children's Hospital, Capital Medical University, National Center for Children's HealthPediatric-type Diffuse High-grade Gliomas

Start: 2025-09-10Updated: 2025-08-25

Evaluation of the Clinical Efficacy of Epigenetic Agents Combined with Immune Checkpoint Inhibitors in the Treatment of Diffuse Midline Glioma

Active, not recruitingChiCTR2500107974

Beijing Children's Hospital, Capital Medical University, National Center for Children's HealthDiffuse midline glioma

Start: 2025-09-10Updated: 2025-08-25

Evaluation of the Clinical Efficacy of Epigenetic Agents Combined with Immune Checkpoint Inhibitors in the Treatment of Diffuse Midline Glioma

Active, not recruitingChiCTR2500108917

Shunyi Women's & Children's Hospital of Beijing Children's HospitalDiffuse midline glioma

Start: 2025-09-10Updated: 2025-09-15